SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731-Reference-Cited by-同舟云学术

SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731

Published:2023-05-10 Issue:3 Volume:4 Page:745-750
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Elgarten Caitlin W.¹^ORCID,Kairalla John A.²,Thompson Joel C.³^ORCID,Miller Tamara P.⁴^ORCID,Wang Cindy²,Conway Susan²,Loh Mignon L.⁵,Raetz Elizabeth A.⁶,Gupta Sumit⁷^ORCID,Rau Rachel E.⁸,Angiolillo Anne⁹,Rabin Karen R.⁸,Alexander Sarah⁷

Affiliation:

1. Department of Pediatrics Division of Oncology Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

2. Department of Biostatistics University of Florida Gainesville Florida USA

3. Department of Pediatrics Division of Hematology/Oncology/Bone Marrow Transplant Children's Mercy Hospital University of Missouri ‐ Kansas City Kansas City Missouri USA

4. Pediatric Hematology/Oncology Children's Healthcare of Atlanta ‐ Egleston Atlanta Georgia USA

5. Ben Towne Center for Childhood Cancer Research Seattle Children's Research Institute and Department of Pediatrics Seattle Children's Hospital University of Washington Seattle Washington USA

6. Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York USA

7. Division of Hematology/Oncology Hospital for Sick Children Toronto Ontario Canada

8. Pediatric Hematology/Oncology Baylor College of Medicine Houston Texas USA

9. Center for Cancer and Blood Disorders Children's National Medical Center Washington District of Columbia USA

Abstract

AbstractHematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID‐19) in adults; however, data specific to children with leukemia are limited. High‐quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard‐risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease‐specific estimate of SARS‐CoV‐2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID‐19‐related death. These data suggest SARS‐CoV‐2 infection does not confer substantial morbidity among young patients with B‐lymphoblastic leukemia/lymphoma (B‐ALL/LLy).

Funder

National Institutes of Health

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.697

Reference17 articles.

1. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)

2. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

3. COVID-19 in Children With Cancer in New York City

4. SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities